MOZ-TIF2-mediated destruction of CBP/p300 is blocked by calpain inhibitor 2.
Kindle
K B
KB
Collins
H M
HM
Heery
D M
DM
D015153:Blotting, Western; D001859:Bone Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D009842:Oligopeptides / Q000494:pharmacology*; D015514:Oncogene Proteins, Fusion / Q000378:metabolism*; D012516:Osteosarcoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D011401:Promoter Regions, Genetic; D018168:Receptors, Retinoic Acid / Q000235:genetics / Q000378:metabolism; D014407:Tumor Cells, Cultured; D050880:p300-CBP Transcription Factors / Q000378:metabolism*
D015853:Cysteine Proteinase Inhibitors; C475973:MOZ-TIF2 protein, human; D009842:Oligopeptides; D015514:Oncogene Proteins, Fusion; D018168:Receptors, Retinoic Acid; C082925:retinoic acid receptor beta; C069861:calpain inhibitor 2; D050880:p300-CBP Transcription Factors